AKT1 and lung cancer: In non‐small cell lung cancer (NSCLC), the cisplatin‐induced release of exosomes enriched with miR‐425‐3p can enhance autophagy by targeting AKT, ultimately leading to chemoresistance and tumor growth, and contributing to the progression of lung cancer.146